Plain Language Summary
What is this summary about?
This summary describes results from a study of preferences for treatment features among patients with a type of blood cancer called multiple myeloma. Treatment features are the characteristics of a treatment, such as how effective it is, how it is administered, and potential side effects.
Why was the study done and how was it conducted?
The aim of this research was to learn more about the most important features of treatment to patients with multiple myeloma. This information can help healthcare professionals, patients, and caregivers choose between different therapies.
Patients with multiple myeloma that had either recurred (relapsed) or did not respond (refractory) to previous therapy completed an online survey. Using the survey results, researchers quantified patient preferences for different treatment features. Researchers made predictions about how patients may choose between different treatments based on their different features.
What were the results and what do they mean?
On average, patients rated the most important feature to be increasing the amount of time they could expect to live after starting the treatment.
Other highly important features included reducing the risk of serious infection, avoiding long hospital stays at the start of treatment, and the increasing likelihood of their cancer responding to treatment (i.e., the treatment reduced the signs of cancer in the body, either partially or completely, to undetectable levels).
Although patients were wary of serious infections, they were willing to trade a higher risk of serious infection to increase how long they could expect to live.
When considering hypothetical treatment options, patients in general preferred a treatment that was immediately available versus one that would not be immediately available.
KEYWORDS: BCMA bispecific antibody, CAR T cell therapy, Patient Preference, Relapsed/refractory multiple myeloma, RRMM
Acknowledgments
The authors thank the patients who participated in this study. Kimberly Moon of RTI Health Solutions provided overall project management for this study.
This is an abstract of the Plain Language Summary of Publication article.
View the full Plain Language Summary PDF of this article to read the full-text
Link to original article here
Disclosure statement
Sikander Ailawadhi reports consultancy fees from GSK, Sanofi, BMS, Takeda, BeiGene, Pharmacyclics, Amgen, Janssen, Regeneron, Cellectar, and Pfizer; and research funding to their institution from GSK, BMS, Pharmacyclics, Amgen, Janssen, Cellectar, AbbVie, and Ascentage. Timothy J. Inocencio, Lei Chi, James Harnett, Glenn S. Kroog, Karen Rodriguez-Lorenc, and Qiufei Ma are employees of Regeneron Pharmaceuticals, Inc. and may hold shares and/or stock options in the company. James Harnett holds stock in Pfizer Inc. Carol Mansfield, Phani Chintakayala, and Cooper Bussberg are full-time employees of RTI Health Solutions, an independent nonprofit research organization, which was retained by Regeneron Pharmaceuticals, Inc. to conduct the research that is the subject of this summary. Jenny Ahlstrom is a patient advisor for Pfizer, BMS, J&J, and Sanofi. This work was supported by Regeneron Pharmaceuticals, Inc. RTI Health Solutions, an independent nonprofit research organization, received funding under a research contract with Regeneron Pharmaceuticals, Inc. to conduct this study and provide publication support in the form of manuscript writing, styling, and submission. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Author contributions
Sikander Ailawadhi: Conceptualization, Methodology, Visualization, Writing - Review & Editing. Timothy J. Inocencio: Conceptualization, Methodology, Visualization, Writing - Review & Editing. Carol Mansfield: Conceptualization, Methodology, Investigation, Data Curation, Visualization, Writing - Review & Editing. Phani Chintakayala: Investigation, Data Curation, Visualization, Writing - Review & Editing. Cooper Bussberg: Investigation, Data Curation, Visualization, Writing - Review & Editing. Lei Chi: Conceptualization, Methodology, Visualization, Writing - Review & Editing. James Harnett: Conceptualization, Methodology, Visualization, Writing - Review & Editing. Glenn S. Kroog: Visualization, Writing - Review & Editing. Karen Rodriguez-Lorenc: Conceptualization, Methodology, Visualization, Writing - Review & Editing. Jenny Ahlstrom: Visualization, Writing - Review & Editing. Qiufei Ma: Conceptualization, Methodology, Visualization, Writing - Review & Editing. All authors approved the final version of the manuscript to be published and agreed to take responsibility for all aspects of the work.
Medical writing and creative support for the development of this summary was provided by Poppie Cooper, MSc, of Oberon, a division of OPEN Health Communications, and was funded by Regeneron Pharmaceuticals, Inc., according to Good Publication Practice guidelines (www.ismpp.org/gpp-2022).
Patient reviewers on this PLSP have received honorarium from Future Oncology for their review work but have no other relevant financial relationships to disclose.
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Funding
This summary was funded by Regeneron Pharmaceuticals, Inc. Authors affiliated with Regeneron Pharmaceuticals Inc. had a role in study design, data collection and analysis, decision to publish, and preparation of the summary.